STOCK TITAN

Medigus Ltd. American Depositary Share - MDGS STOCK NEWS

Welcome to our dedicated page for Medigus Ltd. American Depositary Share news (Ticker: MDGS), a resource for investors and traders seeking the latest updates and insights on Medigus Ltd. American Depositary Share stock.

Medigus Ltd. (NASDAQ: MDGS) is an innovative medical device company renowned for its groundbreaking endoscopic procedures and devices. The company has developed a comprehensive endoscopic system designed for the intraluminal treatment of Gastroesophageal Reflux Disease (GERD), a prevalent chronic condition in the Western world. The centerpiece of Medigus's offering is the SRS system, which integrates a miniaturized video camera, surgical stapler, and ultrasonic sights for precise alignment into a single, flexible endoscope. This unique system allows gastroenterologists and surgeons to perform endoluminal partial anterior fundoplications, thereby eliminating the need for traditional open or laparoscopic surgery, significantly advancing the clinical management of GERD.

Alongside its flagship SRS system, Medigus also designs and manufactures bespoke endoscopy systems for partner companies, leveraging its proprietary technology to meet diverse clinical needs. This dual focus on innovation in GERD treatment and custom endoscopic solutions underscores Medigus's commitment to advancing medical care through minimally invasive techniques.

Based in Israel, Medigus's recent initiatives include strategic partnerships and collaborations to expand the reach and application of their technologies. The company's financial health is bolstered by these partnerships, alongside a strong pipeline of ongoing projects aimed at enhancing patient outcomes and broadening the scope of endoscopic treatments.

For the latest updates, news, and detailed financial information, stakeholders can contact: Tali Dinar, Chief Financial Officer, at ir@medigus.com, or Michal Efraty, Investor Relations, at michal@efraty.com.

Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announced that its subsidiary, Jeffs' Brands Ltd., has entered into a non-binding letter of intent with Sky Growth Partners Ltd. to invest in a DLP laser-based system for drone countermeasure solutions. The investment includes a $2 million investment by Jeffs' Brands, giving it a 70% equity interest in the new company. The system aims to disrupt the operation of cameras on drones and aircrafts, potentially having defense and commercial applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Medigus Ltd. (MDGS) subsidiary, Charging Robotics Ltd., received approval for funding from the Israeli Innovation Authority for a wireless charging pilot project for electric vehicles in automated parking systems. The project aligns with the Israeli Ministry of Energy's goals for EV market adoption and has a total approved budget of approximately NIS 1.2 million ($445,000).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announced the development of Bubbl, a state-of-the-art writing tool utilizing Machine Learning, NLP, AI, and Deep Learning technologies. The Global Writing Enhancement Software market is projected to reach $887.9 million by 2030 with an 11% CAGR from 2023-2030. Bubbl is expected to significantly impact the market for writing tools, offering users an unmatched writing experience with innovative features such as Click Writing and tailored assistive tools for different writing needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
AI
Rhea-AI Summary
Medigus Ltd. reports a 52% increase in revenues for H1 2023, reaching $53.3 million compared to $35 million in H1 2022. Medigus also sold its stake in Odysight.ai Inc. for $5.7 million in cash. Additionally, subsidiary Charging Robotics merged with a US public company and commenced trading on the OTC Market. Viewbix reported a 10% increase in revenues for H1 2023, totaling $48 million. However, the company experienced an operating loss of $9.8 million for the six months ended on June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
-
Rhea-AI Summary
Medigus signs operating agreement for joint venture to purchase and sell commercial property in Miami, FL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.5%
Tags
-
Rhea-AI Summary
Medigus converts $1,240 thousand convertible loan into shares of AI Systems, becoming its largest shareholder with 36% stake.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
AI
Rhea-AI Summary
Medigus announces ParaZero's expansion into Latin American drone market with Black Square partnership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
Rhea-AI Summary
Viewbix Inc., a global marketing technology solutions company, reported $48 million in revenue for the first half of 2023. The second quarter of 2023 showed an 18.5% increase in revenues compared to the same period in 2022. Operating income for the first half of 2023 was $174 thousand, and EBITDA amounted to $1,642 thousand. Net cash from operating activities for the first half of 2023 was $1,015 thousand.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
none
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announced that its subsidiary, ParaZero Technologies Ltd. (PRZO), has received a repeat order for a custom drone safety system from a Fortune 500 automotive manufacturer. The order follows a previous agreement and showcases the company's expertise in providing advanced safety solutions for commercial drones and urban air mobility aircraft.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none

FAQ

What is the current stock price of Medigus Ltd. American Depositary Share (MDGS)?

The current stock price of Medigus Ltd. American Depositary Share (MDGS) is $2.36 as of June 11, 2024.

What is the market cap of Medigus Ltd. American Depositary Share (MDGS)?

The market cap of Medigus Ltd. American Depositary Share (MDGS) is approximately 4.5M.

What does Medigus Ltd. specialize in?

Medigus Ltd. specializes in innovative endoscopic procedures and devices, particularly for the treatment of GERD.

What is the SRS system?

The SRS system is an endoscopic solution that combines a miniaturized camera, surgical stapler, and ultrasonic sights to treat GERD without open or laparoscopic surgery.

How does the SRS system benefit GERD patients?

The SRS system allows for a minimally invasive procedure, reducing the need for more invasive surgeries and potentially improving recovery times.

Does Medigus Ltd. collaborate with other companies?

Yes, Medigus designs and manufactures endoscopy systems for partner companies using its proprietary technologies.

Where is Medigus Ltd. based?

Medigus Ltd. is based in Israel.

Who can I contact for investor relations at Medigus?

For investor relations, you can contact Michal Efraty at michal@efraty.com.

What is the primary medical condition that Medigus's technology addresses?

Medigus's technology primarily addresses Gastroesophageal Reflux Disease (GERD).

How does the SRS system work?

The SRS system uses a flexible endoscope with a built-in camera, stapler, and ultrasonic guide to perform partial anterior fundoplication endoluminally.

What are the recent initiatives of Medigus Ltd.?

Recent initiatives include strategic partnerships and ongoing projects to enhance their technology's reach and applications.

How can I get the latest news about Medigus Ltd.?

You can get the latest news by contacting their Chief Financial Officer Tali Dinar or Investor Relations Michal Efraty, or visiting their official communications.

Medigus Ltd. American Depositary Share

Nasdaq:MDGS

MDGS Rankings

MDGS Stock Data

4.47M
28.42M
0.29%
0.22%
Medical Devices
Healthcare
Link
United States of America
Tel Aviv